{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:40:14Z","timestamp":1792010414565,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti\u2010CD38 antibody TAK\u2010079.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A randomised, double\u2010blind, placebo\u2010controlled trial of a single intravenous (i.v.) infusion or subcutaneous (s.c.) injection of TAK\u2010079 at escalating doses in healthy subjects (<jats:italic>n<\/jats:italic> = 74), who were followed for 92 days postexposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>TAK\u2010079 was well tolerated. All adverse events were mild or moderate. There were no withdrawals, infusion, or injection site reactions over the tested i.v. and s.c. doses up to 0.06 and 0.6 mg\u2009kg<jats:sup>\u22121<\/jats:sup>, respectively. At higher doses, transient cytokine level increases, following i.v. administration, coincided with reduction in CD38\u2010expressing cells; clinical symptoms included mild pyrexia, headache, and postural hypotension. Following an i.v. infusion of 0.06 mg\u2009kg<jats:sup>\u22121<\/jats:sup> TAK\u2010079, maximum observed serum concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) was 100.4 (%CV: 52) ng\u2009mL<jats:sup>\u22121<\/jats:sup>, time to <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was the end of infusion and natural killer (NK_ cells were reduced 93.8 (\u00b18.5) % from baseline levels. Following a s.c. injection of 0.6 mg\u2009kg<jats:sup>\u22121<\/jats:sup> TAK\u2010079, <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> was 23.0 (%CV: 67) ng\u2009mL<jats:sup>\u22121<\/jats:sup> with time to <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> of 24 (range 7.98\u201396.02) hours, and plasmablasts were subsequently reduced 93.4 (\u00b18.8) % from predose levels. Serum immunoglobulin (Ig)M, IgA and IgG levels were reduced by 15\u201360% and had not returned to baseline levels within 78 days after administration at \u22650.3 mg\u2009kg<jats:sup>\u22121<\/jats:sup> s.c. Reductions in NK cells at 0.6 mg\u2009kg<jats:sup>\u22121<\/jats:sup> s.c. were approximately 2\u20133 times more durable than at 0.06 mg\u2009kg<jats:sup>\u22121<\/jats:sup> i.v.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TAK\u2010079 was well tolerated and s.c. administration elicited more durable reductions in plasmablasts and NK cells. This plasmacytolytic profile could be useful for treating disorders caused by plasma or NK cells, malignant counterparts, and\/or pathogenic antibodies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14241","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:09:34Z","timestamp":1581440974000},"page":"1314-1325","source":"Crossref","is-referenced-by-count":47,"title":["Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti\u2010CD38 cytolytic antibody TAK\u2010079 in healthy subjects"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5503-7172","authenticated-orcid":false,"given":"Eric R.","family":"Fedyk","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals International  Deerfield IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International  Deerfield IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelize","family":"Koch","sequence":"additional","affiliation":[{"name":"Parexel  Harrow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glennda","family":"Smithson","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International  Deerfield IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Estevam","sequence":"additional","affiliation":[{"name":"Takeda Oncology  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Chen","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International  Deerfield IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gezim","family":"Lahu","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Roepcke","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchang","family":"Lin","sequence":"additional","affiliation":[{"name":"Takeda Oncology  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachy","family":"Mclean","sequence":"additional","affiliation":[{"name":"Takeda California  San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1578-z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.11.1074"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30466"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.008"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40180"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1324"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(04)00048-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21056"},{"issue":"3","key":"e_1_2_10_10_1","first-page":"369","article-title":"Invariant NKT cells produce IL\u201017 through IL\u201023\u2010dependent and \u2010independent pathways with potential modulation of Th17 response in collagen\u2010induced arthritis","volume":"22","author":"Yoshiga Y","year":"2008","journal-title":"Int J Mol Med"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319301"},{"key":"e_1_2_10_12_1","volume-title":"DARZALEX\u00ae (daratumumab) injection [prescribing information]","author":"Biotech J","year":"2015"},{"issue":"1","key":"e_1_2_10_13_1","first-page":"224","article-title":"TAK\u2010079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion","volume":"198","author":"Smithson G","year":"2017","journal-title":"J Immunol"},{"issue":"10","key":"e_1_2_10_14_1","first-page":"1085","article-title":"The anti\u2010CD38 monoclonal antibody TAK\u2010079 depletes antibody secreting cells from normal and SLE patients [2016 ACR\/ARHP annual meeting abstract 1085]","volume":"68","author":"Wang X","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.402"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.256602"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14153"},{"issue":"1","key":"e_1_2_10_18_1","first-page":"127","article-title":"CD38+ cell depletion with TAK\u2010079 reduces arthritis in a cynomolgus collagen\u2010induced arthritis (CIA) model","volume":"198","author":"Smithson G","year":"2017","journal-title":"J Immunol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0477-1"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.577"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T10:16:47Z","timestamp":1692785807000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/bcp.14241"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14241","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,22]]}}}